- Nachrichtendetail
-
20.06.2024 14:55:03 - dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
GILEAD SCIENCES DL-,001 | 885823 | Frankfurt | 64,150 | 01.07.24 18:06:11 | -0,220 | -0,34% | 64,020 | 64,040 | 63,880 | 64,370 |
